Trxade Health Stock Fair Value Calculation – TRxADE Health Receives Nasdaq Notice for Delayed Form 10-Q Filing

🌧️Trending News

TRXADE ($NASDAQ:MEDS): TRxADE Health, a leading provider of integrated pharmacy solutions, has recently received a notice from Nasdaq for the late filing of its Form 10-Q. TRxADE Health’s stock is currently listed on the Nasdaq Global Market. The company specializes in bringing together independent pharmacies, out-of-network pharmaceutical suppliers, and patients to facilitate access to prescription medications at more competitive prices. TRxADE Health received a letter from Nasdaq informing them that the company is not in compliance with the filing requirements. TRxADE Health has been taking steps to ensure that it remains compliant with Nasdaq requirements. The company has engaged an independent registered public accounting firm to assist in the review of its financial statements and disclosures.

Additionally, TRxADE Health has submitted a response to Nasdaq’s letter and is working with Nasdaq to provide regular updates on progress made toward completing the filing. The late filing of the Form 10-Q does not impact day-to-day operations of TRxADE Health. The company will continue to provide exceptional services to its customers while it works to bring its filing into compliance. Nasdaq encouraged TRxADE Health to seek advice from legal counsel to ensure timely compliance with the exchange’s filing requirements.

Share Price

In response to the notice, TRXADE HEALTH stock opened at $5.6 and closed at $5.8, representing a 3.5% increase from its previous closing price of $5.6. The notice highlighted that the company was overdue in filing its Form 10-Q, which is a quarterly report filed with the US Securities and Exchange Commission (SEC) that provides investors with information on the company’s financial and operating performance. The Nasdaq Notice did not have any immediate effect on the company’s stock price as it continued to trade in positive territory. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Trxade Health. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Trxade Health. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Trxade Health. More…

Key Ratios Snapshot

Some of the financial key ratios for Trxade Health are shown below. More…

Analysis – Trxade Health Stock Fair Value Calculation

GoodWhale recently conducted an analysis of TRXADE HEALTH, a healthcare technology company that provides services to both retailers and independent pharmacies. Our proprietary Valuation Line analysis determined the intrinsic value of a TRXADE HEALTH share to be around $12.7. However, the current stock price for TRXADE HEALTH is only $5.8, meaning it is undervalued by 54.3%. This indicates that investors have a great opportunity to purchase TRXADE HEALTH stock at a substantial discount. We believe that investing in TRXADE HEALTH now could result in strong returns in the future. More…

Peers

It provides a comprehensive solution for medical professionals to efficiently manage their supplies, order medications and compare prices. The company competes in the industry with Jianzhijia Pharmaceutical Chain Group Co Ltd, LifeStance Health Group Inc, and Oriola Corp. Each of these companies offer their own unique products and services to customers in the healthcare industry.

– Jianzhijia Pharmaceutical Chain Group Co Ltd ($SHSE:605266)

Jianzhijia Pharmaceutical Chain Group Co Ltd is a major player in the pharmaceutical industry. The company specializes in the production and sale of pharmaceuticals and related products. As of 2023, the company’s market cap stands at 7.47B, making it one of the larger companies in its sector. Its Return on Equity (ROE) of 14.68% reflects the company’s solid financial performance, indicating a strong return on its shareholders’ equity. The company’s success is further validated through its impressive market capitalization, which has grown significantly since its inception.

– LifeStance Health Group Inc ($NASDAQ:LFST)

LifeStance Health Group Inc is a provider of behavioral health care services. Founded in 2019, the company has grown to become one of the largest behavioral health care providers in the United States. As of 2023, LifeStance Health Group Inc’s market cap stands at 3.18 billion USD, making it one of the most valued companies in the industry. In terms of performance, the company boasts a negative Return on Equity (ROE) of -7.46%, indicating that the company currently is not generating any profits from its investments. The company’s main focus is on providing quality mental and behavioral health services to their customers.

– Oriola Corp ($LTS:0NER)

Oriola Corp is a Finnish public health and wellbeing company founded in 1923 that specializes in pharmaceuticals, medical supplies and consumer health products. With a market cap of 262.37M as of 2023, the company is currently one of the top players in the health and wellbeing sector. Oriola Corp’s Return on Equity (ROE) of 2.64% indicates that they are able to generate a healthy return on their equity investments, further demonstrating their efficiency and ability to achieve financial success.

Summary

TRxADE Health is a pharmaceutical company listed on Nasdaq that recently received a notice from Nasdaq for late filing of its Form 10-Q. The company’s stock price has moved up slightly the same day, indicating that investors may be optimistic about the company’s future prospects. Investors should also pay attention to any further developments regarding the late filing with Nasdaq and assess the potential impact this could have on their decisions. It is important to note that this is a short-term move and investors should research the company thoroughly before making any investment decisions.